By Indication

Nasolacrimal Duct Obstruction (NLDO) & Epiphora Market Analysis

Cross-industry research covering Nasolacrimal Duct Obstruction (NLDO) & Epiphora across 1 market reportspanning Pharmaceuticals & Medical Devices — Ophthalmic Surgery.

1 Reports

1 Industries

Reports Covering Nasolacrimal Duct Obstruction (NLDO) & Epiphora

Oculoplastic Surgery Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR

Pharmaceuticals & Medical Devices — Ophthalmic Surgery·Market: USD 4.8 Billion (2025)·CAGR: 7.2%

Primary acquired NLDO is strongly age-related and drives DCR surgical volumes; adjuvant antifibrotic agents (NCT07154121) represent an emerging pharmacological component of this historically purely surgical indication, potentially adding a pharmaceutical revenue layer post-procedure.

11%

Market Share

5.6%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments